pharmind: Modellierung und Simulation in der pädiatrischen Arzneimittelentwicklung
Published: December 21, 2023
This is the article written in German, published on pharmind.
Children’s physiological functions are different from those of adults due to their growth and maturation processes. The limited availability of clinical trial data involving children makes it challenging to make evidence-based decisions regarding the use of drugs in this population. Research involving children also raises ethical considerations that must be addressed alongside the regulatory requirements for safety and efficacy.
Drug regulatory authorities acknowledge the potential of modeling and simulation in the development of pediatric medications. By using quantitative computer models to extrapolate findings from adult studies, researchers can optimize dosing regimens and facilitate the approval of medicines for children.
This article provides an overview of the ethical and regulatory aspects of pediatric drug development, as well as the role of modeling and simulation in this field.
Authors: Author: Nele Mueller-Plock, PhD, Amy Cheung, PhD, Eva Berglund, PhD, Justin Hay, PhD
Learn more about Pediatric Drug Development
Certara is transforming pediatric drug development with innovative modeling, simulation, and regulatory strategies. Our unique Pediatric MIDD approach integrates cutting-edge biosimulation with regulatory science, enabling the design of pediatric programs that meet global regulatory standards and ensure safe, effective medicines for children.
Sign up to newsletter
Why sign up? Because transforming drug development is not just our goal—it’s our obsession. If it’s yours too, then be the first to know of new insights and join us in pushing the boundaries of science.
